Vanguard UK 2026Q1: $115.74B First-File With AZN Tilt

Vanguard Asset Management Ltd — the UK-domiciled subsidiary of the Vanguard complex — appears in our 13F dataset for the first time at $115.74 billion of US-equity exposure across 2,395 reported positions for 2026Q1. This is the kind of filer that institutional-coverage outlets routinely confuse with the parent Vanguard Capital Management sleeve in Pennsylvania, then misclassify either as "smart money" or as a fresh whale signal. Neither read holds: Vanguard Asset Management Ltd is a passive-index complex whose 13F is best understood as a snapshot of how a foreign-domiciled passive sleeve mirrors — and slightly diverges from — the US benchmark book the parent runs.

The mechanical structure is what makes the file useful. NVIDIA sits at the top at $7.12B (6.53% of book), Apple at $6.36B (5.83%), Microsoft at $4.72B (4.33%), then a UK-domiciled outlier — AstraZeneca PLC (CUSIP G0593M107) at $3.62B (3.33%) — wedged between MSFT and Amazon at $3.47B. That AZN line is the structural tell: the UK sleeve carries home-market large-caps at index-overweight relative to a US-only benchmark, which is exactly what a UK-domiciled passive vehicle should do.

The top-10 read

The full top-10 from the 2026Q1 file:

• NVDA — $7.12B (6.53%)
• AAPL — $6.36B (5.83%)
• MSFT — $4.72B (4.33%)
• AstraZeneca PLC (CUSIP G0593M107) — $3.62B (3.33%) — UK home-market overweight
• AMZN — $3.47B (3.18%)
• GOOGL — $2.89B (2.65%)
• AVGO — $2.47B (2.26%)
• GOOG — $2.37B (2.18%)
• META — $2.16B (1.99%)
• TSLA — $1.82B (1.67%)

Two reads come out of this:

1. Top 10 = ~33.95% of book. That is materially less concentrated than a sector-active sleeve and slightly more concentrated than a pure float-cap S&P tracker (which would typically sit at 30-32%). The UK-domicile tilt explains the gap — AstraZeneca alone adds roughly 3.3 percentage points of concentration that a US-only tracker would not carry.
2. The dual-class Alphabet split (GOOGL + GOOG combined = 4.83%) is exactly what a strict cap-weight passive would produce. No discretion is being applied.

What the concentration profile tells you

The pie above shows the same data but flipped to a "top 5 + tail" view: top 5 names = ~25% of book, the remaining 90+% of the holdings list = 75% of NAV. That long-tail distribution is the signature of a market-cap-weighted passive vehicle. Active conviction sleeves — Sands Capital, Akre Focus, Polen Growth — typically run top-5 concentration north of 35%, sometimes 50%+. Sovereign wealth funds (Norges Bank) sit in the 8-12% range. Vanguard Asset Management Ltd's ~25% top-5 is squarely passive.

The practical consequence for any reader scanning the file: don't read this as conviction. The presence of NVDA at the top is index math, not thesis. The presence of AstraZeneca at #4 is UK-domicile math, not a pharma view. The whole book moves with the underlying benchmark and the sleeve's net subscription/redemption flow.

The AUM growth context

The AUM history chart only carries one bar — 2026Q1 at $115.74B — because this is the first quarter the sleeve appears in our 13F dataset under this CIK (0001680208). That is itself diagnostic: the UK-domiciled Vanguard book either (a) crossed a SEC reporting threshold for the first time, (b) restructured its US-equity reporting entity, or (c) received subscription inflows large enough to materialize as a new institutional 13F filer in the SEC EDGAR system.

For comparison, the US parent Vanguard Capital Management LLC reports approximately $4.0 trillion of 13F US-equity exposure as of 2025Q4. The UK sleeve's $116B is roughly 2.9% of that — consistent with the share of Vanguard's global AUM domiciled in or distributed through the UK, which trade press estimates places in the 3-5% range.

What this filer is — and is not

Filer-classification matters because the platform and our editorial system filter passive sleeves out of "smart money" surfaces by design. Vanguard Asset Management Ltd's `filerType` is unclassified at the moment of writing, but its book composition (broad market-cap weight + UK home-market tilt + ~25% top-5 concentration + ~2,400 positions) is structurally identical to the passive cohort. Treating it as conviction would put it in the same misread bucket as treating BlackRock or State Street sleeves as active — which the platform's EXCLUDED_FILER_TYPES_FOR_SMART_MONEY taxonomy explicitly excludes for good reason.

What the file is useful for: a benchmark snapshot for foreign-domiciled passive flow into US equities, an early-quarter signal of how UK-listed names (AZN here, potentially Shell / GSK / HSBC in subsequent quarters) get re-aggregated through US-13F reporting, and a clean reference book for analysts modeling cross-border passive demand.

What to verify next

1. The next two 13F filings (Q2 2026 due Aug 14, 2026; Q3 2026 due mid-November). Whether the $115.74B base sustains, grows with subscription flow, or contracts on redemptions tells you whether the new SEC-reporting structure is permanent or transitional.
2. The composition of names #11-50. The top 10 carries the UK home-market tilt; positions ranked 11-50 will reveal whether the rest of the sleeve also overweights UK + Continental European names re-aggregated via ADR, or whether the tilt collapses to pure US-cap-weight outside the top of the book.
3. Any 13G/A filings under this CIK. Passive sleeves of this size routinely file 13G threshold-cross amendments; the cadence and target names will reveal which US issuers the UK sleeve is structurally over-allocated to relative to the parent.

You can pull the full 2,395-position holdings table for Vanguard Asset Management Ltd directly from the platform, plus comparison surfaces for the parent Vanguard Capital Management. The smart-money signal feed aggregates the active-manager moves the passive sleeves track around.